

# SOLICITOR

AO 120 (Rev. 2/99)

DEC 19 2008

TO: Mail Stop 8 Director of the U.S. Patent & Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450	REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK
---	---

In Compliance with 35 § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been  
filed in the U.S. District Court Northern District of California on the following ☒ Patents or ☐ Trademarks:

DOCKET NO. CV 08-05590 HRL	DATE FILED 12/16/2008	U.S. DISTRICT COURT 280 South First Street, Rm 2112, San Jose, CA 95113
PLAINTIFF MEDIMMUNE		DEFENDANT PDL BIOPHARMA
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1 5,585,089		SEE ATTACHED COMPLAIN
2 5,693,761		
3 5,693,762		
4 6,180,370		
5 7,022,500		

In the above—entitled case, the following patent(s) have been included:

DATE INCLUDED	INCLUDED BY <input type="checkbox"/> Amendment <input type="checkbox"/> Answer <input type="checkbox"/> Cross Bill <input type="checkbox"/> Other Pleading			
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK		
1				
2				
3				
4				
5				

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT
--------------------

CLERK Richard W. Wieking	(BY) DEPUTY CLERK Betty Walton	DATE December 17, 2008
-----------------------------	-----------------------------------	---------------------------

Copy 1—Upon initiation of action, mail this copy to Commissioner Copy 3—Upon termination of action, mail this copy to Commissioner  
Copy 2—Upon filing document adding patent(s), mail this copy to Commissioner Copy 4—Case file copy

1 JEFFREY E. FAUCETTE (No. 193066)  
Email: jfaucette@howardrice.com  
2 HOWARD RICE NEMEROVSKI CANADY  
FALK & RABKIN  
3 A Professional Corporation  
Three Embarcadero Center, 7th Floor  
4 San Francisco, California 94111-4024  
Telephone: 415/434-1600  
5 Facsimile: 415/217-5910

6 GERSON A. ZWEIFACH  
PAUL B. GAFFNEY  
7 AARON P. MAURER  
DAVID I. BERL (No. 211761)  
8 WILLIAMS & CONNOLLY LLP  
725 Twelfth Street, NW  
9 Washington, DC 20005-5901  
Telephone: 202/434-5000  
10 Facsimile: 202/434-5029

11 ELLIOT M. OLSTEIN  
CARELLA, BYRNE, BAIN, GILFILLAN,  
12 CECCHI, STEWART & OLSTEIN, P.C.  
Five Becker Farm Road  
13 Roseland, New Jersey 07068-1739  
Telephone: 973/994-1700  
14 Facsimile: 973/994-1744

15 Attorneys for Plaintiff MEDIMMUNE, LLC

16 UNITED STATES DISTRICT COURT  
17 NORTHERN DISTRICT OF CALIFORNIA  
18 SAN FRANCISCO DIVISION

19  
20 MEDIMMUNE, LLC,

21 Plaintiff,

22 v.

23 PDL BIOPHARMA, INC.,

24 Defendant.  
25  
26  
27  
28

CV 08  
No. 5590

COMPLAINT FOR DECLARATORY  
JUDGMENT OF PATENT INVALIDITY  
AND CONTRACTUAL RIGHTS

03 DEC 16 AM 10:41  
CLERK OF DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA

HRL

HOWARD  
RICE  
NEMEROVSKI  
CANADY  
FALK  
& RABKIN  
A Professional Corporation

14 130

1  
2  
3  
4  
5  
6  
7  
8  
9  
10

## COMPLAINT

11 Plaintiff MedImmune, LLC (f/k/a MedImmune, Inc.), by its attorneys, for its  
12 Complaint, alleges as follows:

13 1. This is an action for declaratory relief pursuant to Federal Rule of Civil  
14 Procedure 57 and 28 U.S.C. §§2201. MedImmune seeks a declaration that U.S. Patent Nos.  
15 5,585,089, 5,693,761, 5,693,762, 6,180,370, and 7,022,500 are invalid, and that  
16 MedImmune owes no payments under a patent license agreement with PDL BioPharma, Inc.  
17 (f/k/a Protein Design Labs, Inc.), ("PDL"), assignee of the patents.  
18  
19

20  
21  
22  
23  
24  
25  
26  
27  
28

## PARTIES, JURISDICTION, AND VENUE

11 2. Plaintiff MedImmune, LLC. ("MedImmune") is a biotechnology company with  
12 its principal place of business in Gaithersburg, Maryland. MedImmune uses biotechnology  
13 to develop and produce antibody therapies, including for the prevention of serious lower  
14 respiratory tract disease caused by respiratory syncytial virus ("RSV") in vulnerable infants.

15 3. PDL is a biopharmaceutical company with its headquarters at 1400 Seaport  
16 Blvd., Redwood City, CA. On information and belief, PDL is the assignee of United States  
17 Patent Nos. 5,585,089, 5,693,761, 5,693,762, 6,180,370, and 7,022,500 (collectively, "the  
18 PDL patents"), entitled Humanized Immunoglobulins, directed to, *inter alia*, certain  
19 humanized antibodies and methods of preparing such antibodies. PDL is the successor-in-  
20 interest of PDL BioPharma, Inc.

21 4. On information and belief, PDL's headquarters in Redwood City are its only  
22 place of business in the United States.

23 5. This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§1331, 1337,  
24 1338(a), and 2201. This Court has jurisdiction over any state law claims asserted hereunder  
25 pursuant to 28 U.S.C. §1367.

26 6. This Court has personal jurisdiction over Defendant PDL because the company  
27 has its principal place of business in this district and, on information and belief, regularly  
28 transacts business within this District in a substantial, continuous and systematic way.

1 7. Venue is proper in this district pursuant to 28 U.S.C. §§1391 and 1400(b),  
2 because PDL has its principal place of business in this district, resides in this district and is  
3 subject to personal jurisdiction in this district.  
4

### 5 BACKGROUND

6 8. In 1997, PDL BioPharma, Inc., the predecessor-in-interest of PDL granted the  
7 predecessor-in-interest of MedImmune a license to develop, manufacture, and sell anti-RSV  
8 anti-bodies that would otherwise infringe a valid claim of certain patents of PDL, including  
9 the PDL patents, in exchange for a royalty on sales of such products (hereinafter, "License  
10 Agreement").

11 9. In the 1990s MedImmune developed the humanized antibody palivizumab for the  
12 treatment of RSV. Palivizumab received FDA approval in 1998 and has been sold since  
13 then under the trade name Synagis®. Since then MedImmune has made regular royalty  
14 payments to PDL under the License Agreement on sales of Synagis®.

15 10. MedImmune has developed a next-generation anti-RSV antibody, motavizumab.  
16 A Biologic License Application to market motavizumab for the prevention of lower  
17 respiratory tract disease caused by RSV was filed by MedImmune in January 2008 and  
18 accepted for filing as a standard application in March 2008. MedImmune has prepared  
19 commercial quantities of motavizumab and expects to initiate marketing of this product upon  
20 FDA approval.

21 11. PDL has taken the position that the PDL patents are valid and that both Synagis®  
22 and motavizumab infringe the PDL patents.  
23

### 24 COUNT I—DECLARATORY JUDGMENT OF INVALIDITY

25 12. MedImmune incorporates each of the preceding paragraphs as if fully set forth  
26 herein.

27 13. United States Patent No. 5,585,089 is invalid under 35 U.S.C. §§101, 102, 103,  
28 112, *et seq.* and/or under the judicially created doctrine of obviousness type double

COMPL. FOR DECLARATORY JUDGMENT OF PATENT INVALIDITY

1 patenting.

2 14. United States Patent No. 5,693,761 is invalid under 35 U.S.C. §§101, 102, 103,  
3 112, *et seq.* and/or under the judicially created doctrine of obviousness type double  
4 patenting.

5 15. United States Patent No. 5,693,762 is invalid under 35 U.S.C. §§101, 102, 103,  
6 112, *et seq.* and/or under the judicially created doctrine of obviousness type double  
7 patenting.

8 16. United States Patent No. 6,180,370 is invalid under 35 U.S.C. §§101, 102, 103,  
9 112, *et seq.* and/or under the judicially created doctrine of obviousness type double  
10 patenting.

11 17. United States Patent No. 7,022,500 is invalid under 35 U.S.C. §§101, 102, 103,  
12 112, *et seq.* and/or under the judicially created doctrine of obviousness type double  
13 patenting.

14 18. MedImmune hereby seeks a declaratory judgment that each of the PDL patents is  
15 invalid under 35 U.S.C. §§101, 102, 103, 112, *et seq.* and/or under the judicially created  
16 doctrine of obviousness type double patenting.

17  
18 **COUNT II—DECLARATORY JUDGMENT OF**  
19 **CONTRACTUAL RIGHTS**

20 19. MedImmune incorporates each of the preceding paragraphs as if fully set forth  
21 herein.

22 20. Royalties are owed under the License Agreement for Synagis® and motavizumab  
23 manufactured and sold in the U.S. only if the development, importation, manufacture, use, or  
24 sale of Synagis® and/or motavizumab would, but for the License Agreement, infringe a  
25 valid claim of the PDL patents.

26 21. Because the parties dispute whether Synagis® and motavizumab whether the  
27 PDL patents are valid, an actual controversy exists between the parties concerning the rights  
28 and obligations of MedImmune under the terms of the License Agreement.

COMPL. FOR DECLARATORY JUDGMENT OF PATENT INVALIDITY

22. MedImmune has no obligation to make payments to PDL under the License Agreement pertaining to Synagis® or motavizumab that is manufactured and sold, because Synagis® and motavizumab do not infringe any valid claim of the PDL patents. The basis for invalidity of the PDL Patents arises under the patent laws of the United States, 35 U.S.C. §§101, 102, 103, 112, *et seq.* and/or the judicially created doctrine of obviousness type double patenting.

23. MedImmune hereby seeks a declaratory judgment that it owes no payments under the License Agreement pertaining to Synagis® or motavizumab, that is manufactured and sold in the United States, and that any payments made to PDL under the License Agreement, post-dating this Complaint, based on sales of Synagis® or motavizumab, that is manufactured, sold and used in the United States, are subject to the equitable powers of the Court.

#### PRAYER FOR RELIEF

WHEREFORE, plaintiff MedImmune requests that judgment be entered in favor of MedImmune and against PDL and requests the following relief:

(a) A declaration that the PDL patents are invalid under 35 U.S.C. §§101, 102, 103, 112, *et seq.* and/or the judicially created doctrine of obviousness type double patenting;

(b) A declaration that PDL is not entitled to any royalties on sales of Synagis® and motavizumab that is manufactured and sold in the United States because the PDL patents are invalid;

(c) A declaration that this is an exceptional case and an award of attorneys' fees pursuant to 35 U.S.C. §285;

(d) Costs and expenses in this action; and

1 (e) Such further and other relief as this Court may deem just and proper.


2 DATED: December 15, 2008.

3 Respectfully,

4 GERSON A. ZWEIFACH  
5 PAUL B. GAFFNEY  
6 AARON P. MAURER  
7 DAVID I. BERL  
8 WILLIAMS & CONNOLLY LLP

9 ELLIOT M. OLSTEIN  
10 CARELLA, BYRNE, BAIN, GILFILLAN,  
11 CECCHI, STEWART & OLSTEIN, P.C.

12 JEFFREY E. FAUCETTE  
13 HOWARD RICE NEMEROVSKI CANADY  
14 FALK & RABKIN  
15 A Professional Corporation

16 By:  JEFFREY E. FAUCETTE

17 Attorneys for Plaintiff MEDIMMUNE, LLC

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
HOWARD  
RICE  
NEMEROVSKI  
CANADY  
FALK  
& RABKIN  
A Professional Corporation